GlassScriptPhysician profile
Chandra P Sanwal
NPI 1235662735
$3,294.48
in general payments reported to CMS, 2019-2025
32 companies · $335 in 2025
The $335 reported for 2025 was less than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $417 · 2021: $958 · 2022: $767 · 2023: $680 · 2024: $137 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,081 · Education: $71.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,081.49 |
| Education | $71.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $362.51 | 2021-2023 | Jakafi |
| Celgene Corporation | $361.64 | 2020-2023 | Reblozyl |
| Seagen INC. | $350.88 | 2021-2023 | Tukysa, Padcev, Adcetris |
| Eisai INC. | $335.49 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $232.11 | 2020-2024 | Keytruda |
| Lilly USA, LLC | $160.91 | 2020-2023 | Verzenio, Retevmo, Jaypirca |
| Abbvie INC. | $143.11 | 2020-2021 | |
| Glaxosmithkline, LLC. | $138.98 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $124.69 | 2025 | Breyanzi |
| Astellas Pharma US INC | $120.29 | 2021-2022 | |
| Pfizer INC. | $112.48 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $109.01 | 2022-2025 | Tagrisso |
| Genzyme Corporation | $85.12 | 2020-2023 | |
| Janssen Biotech, INC. | $71.94 | 2024-2025 | Rybrevant, Carvykti, Tecvayli |
| Daiichi Sankyo INC. | $70.82 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $68.77 | 2020 | |
| Mirati Therapeutics, INC. | $63.90 | 2023 | Krazati |
| Takeda Pharmaceuticals U.S.A., INC. | $55.32 | 2021-2023 | Alunbrig |
| Aveo Pharmaceuticals, INC. | $37.02 | 2025 | |
| Jazz Pharmaceuticals INC. | $34.24 | 2022-2025 | |
| Genmab U.S., INC. | $32.65 | 2024 | Epkinly |
| Gilead Sciences, INC. | $27.03 | 2024 | |
| Sumitomo Pharma America, INC. | $25.16 | 2025 | Orgovyx |
| Deciphera Pharmaceuticals INC. | $22.22 | 2023 | Qinlock |
| Ipsen Biopharmaceuticals, INC | $20.82 | 2025 | Onivyde |
| Sanofi-Aventis U.S. LLC | $20.80 | 2020 | |
| Morphosys, US INC. | $19.57 | 2022 | |
| Exelixis INC. | $18.83 | 2024 | Cabometyx |
| Adc Therapeutics America, INC. | $18.60 | 2022 | |
| Adaptive Biotechnologies Corporation | $17.39 | 2022 | |
| Organon LLC | $17.28 | 2022 | |
| Stemline Therapeutics INC. | $14.90 | 2023 | Orserdu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandra Sanwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.